Celgene-backed CRISPR company emerges with $68M Series A – BioPharma Dive
Endpoints News |
Celgene-backed CRISPR company emerges with $68M Series A
BioPharma Dive After an 18-month stealth period, Repare Therapeutics has burst into the limelight with a $68 million Series A funding, a CRISPR-enabled synthetic lethality drug discovery platform and a pipeline of three preclinical programs targeting "vulnerabilities … CRISPR crew's lab test spotlights lead program in sickle cell disease, beta-thalassemia Analyst Recommendations And Earnings Forecast: CRISPR Therapeutics AG (CRSP), JD.com, Inc. (JD) Crispr Theraptc (CRSP) Given $26.75 Consensus Target Price by Brokerages |
